section name header

Pronunciation

RIF-a-MYE-sin

Classifications

Therapeutic Classification: anti-infectives

Pharmacologic Classification: rifamycins

Indications

REMS


Action

  • Inhibits bacterial synthesis by binding to bacterial DNA-dependent RNA polymerase.
Therapeutic effects:
  • Decreased severity of travelers' diarrhea.

Spectrum:

Pharmacokinetics

Absorption: Poorly absorbed (<0.1%), action is primarily in GI tract.

Distribution: Concentrated in gut.

Metabolism/Excretion: Primarily excreted in feces (86%).

Half-Life: Unknown.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknownunknownunknown



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Aemcolo

Code

NDC Code